Jaw-in-a-day (JIAD) for malignant indications: A systematic review

Jaw-in-a-day (JIAD) achieves resection, maxillofacial reconstruction and immediate dental rehabilitation. While increasingly used, evidence in oncologic populations remains limited. Our objective was to review JIAD in patients with head and neck cancer (HNC) and its outcomes.

Our systematic review was conducted following a predefined protocol (PROSPERO CRD420251043510). Our search strategy was executed on MEDLINE, Embase, CENTRAL, Web of Science, and CINAHL from January 2013 to October 2025. Studies with HNC patients of all ages who underwent JIAD were included. The Methodological Index for Non-Randomized Studies (MINORS) was used for risk of bias assessment.

Nine studies were included with 57 patients. Common tumour characteristics included mandibular location (n = 31; 54.4 %) and squamous cell carcinoma pathology (n = 37; 64.9 %). A fibular free flap was used in all cases (n = 57; 100 %). Majority underwent adjuvant therapy (n = 36; 63.2 %). Prosthesis survival was reported in 6 studies (n = 25/32; 78.1 %) with follow-up periods ranging from 5 to 52 months. Prosthesis removal was commonly due to osteoradionecrosis (ORN) (n = 6; 10.5 %). All irradiated implants had successful early osseointegration (n = 99; 100 %). Delayed implant failure was reported in 4 patients (n = 4/36; 11.1 %) with 11 implants in radiotherapy field (n = 11/99; 11.1 %).

JIAD for HNC patients can have high success in majority of select patients/defects. Although early osseointegration rates were high, oncologic patients receiving adjuvant radiation may remain at elevated risk for ORN-associated prosthesis failure. As such, the risks and benefits of JIAD should be carefully reviewed with the patient, and cancer staging should also be considered.